Cargando…
Canagliflozin: A Novel SGLT2 Inhibitor for Type 2 Diabetes Mellitus
Diabetes Mellitus continues to be a major non- communicable disease with global burden of 366 million at present and projected to increase to 439 to 552 million by 2030, India being the hub of diabetes. Sodium glucose transporter 2 (SGLT2) inhibitors presents a new class of anti-diabetic drugs havin...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3978932/ https://www.ncbi.nlm.nih.gov/pubmed/24741548 http://dx.doi.org/10.4103/1947-2714.128471 |